Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
Primary chemoresistance to platinum-based treatment is observed in approximately 33% of individuals diagnosed with ovarian cancer; however, conventional clinical markers exhibit limited predictive value for chemoresistance. This study aimed to discover new genetic markers that can predict primary re...
Saved in:
Main Authors: | Wang Caixia, Peng Changsheng, Xie Chuan |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2025-01-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2024-1084 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transcription factor A, mitochondrial promotes lymph node metastasis and lymphangiogenesis in epithelial ovarian carcinoma
by: Wubuli Reziwanguli, et al.
Published: (2025-02-01) -
Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01) -
Identification of mitophagy-related biomarkers and immune infiltration in polycystic ovarian syndrome by bioinformatic study
by: Hongjuan Ye, et al.
Published: (2025-02-01) -
Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01) -
Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mTOR axis
by: Wang Fang, et al.
Published: (2023-09-01)